SCHEMBL9892653

SCHEMBL9892653

O=C(O)Cc1cc(C(F)(F)F)ccc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.56
PSEN2 P49810 1/20 0.56
APH1B Q8WW43 1/20 0.56
NCSTN Q92542 1/20 0.56
APH1A Q96BI3 1/20 0.56
PSENEN Q9NZ42 1/20 0.56
PTGDR2 Q9Y5Y4 8/20 0.56
RXRA P19793 3/20 0.54
RXRB P28702 3/20 0.54
RXRG P48443 3/20 0.54
PTGS1 P23219 1/20 0.48
BACE1 P56817 1/20 0.47
FABP4 P15090 1/20 0.45
TBXA2R P21731 1/20 0.44
PTGDR Q13258 1/20 0.44
TACR1 P25103 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9892691 0.88 PTGDR2 (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9892681 0.88 PTGDR2 (0.59) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9892655 0.87 PTGDR2 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9892659 0.87 PTGDR2 (0.59) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9892679 0.84 PTGDR2 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL27682241 0.83 PTGDR2 (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3729702 0.83 PSEN1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9890672 0.82 PSEN1 (0.61) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9890640 0.82 PTGER1 (0.53) PTGDR2RXRARXRBRXRGALDH1A1
SCHEMBL9890676 0.81 PSEN1 (0.59) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PSEN1 2126/4885PSEN2 1867/4885APH1B 3431/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PSEN1 2126/4885PSEN2 1867/4885APH1B 3431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.